CNS Pharmaceuticals Inc
cnspharma.comWhat Do They Do?
Develops therapies for neurological and cancer conditions and seeks to add drug candidates to its pipeline, while exploring licensing of its brain-cancer programs.
10-K for FY2025, filed Mar 31, 2026CNS Pharmaceuticals, Inc. (“CNS,” the “Company,” “we,” “us,” or “our”) is a biotechnology company focused on developing innovative…View ↗
On March 11, 2026, we announced a new corporate growth strategy focused on building a high-value pipeline in neurology and oncology. This…View ↗
Also on March 11, 2026, as part of our new corporate strategy, we announced that we are pivoting from the Company’s historical singular…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$2.6MView ↗
- ▲ +9% (Loss)
- vs −$2.4M in Q2 FY2025
From brain tumors to a broader pipeline
The earlier report centers on developing anti-cancer candidates for brain and central nervous system tumors, especially Berubicin; the latest describes a neurology-and-oncology pipeline strategy built around acquiring or licensing assets, while seeking to license out its legacy brain-cancer programs.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026
Who Do They Compete With?
Competes with Biogen, UCB, Novartis, AbbVie, Eisai, AstraZeneca, Bristol-Myers Squibb, Roche, Merck &, Pfizer, Eli Lilly, Johnson & Johnson, Roivant, Ligand Pharmaceuticals, and Fortress Biosciences
10-K for FY2025, filed Mar 31, 2026Our strategic expansion into neurology brings us into competition with one of the broadest and most active therapeutic areas in the…View ↗
Loading...
